The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Daiichi Sankyo to Transfer Avastin Biosimilar to Amgen in Japan
January 8, 2025
-
ORGANIZATION 4-Ministers’ Pact Has Effectively Been Scrapped with 2025 Off-Year Revision Plan: FPMAJ Chair
January 7, 2025
-
ORGANIZATION As 2025 Begins, Industry Leaders Renew Resolve towards Next Reforms
January 6, 2025
-
REGULATORY Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
-
REGULATORY Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
-
REGULATORY Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
-
TRENDS Top 10 PHARMA JAPAN Articles of 2024
December 25, 2024
-
REGULATORY Deferred PMP Cuts Likely to Batter Stelara; 7 Drugs Subject to Rule after LOE
December 24, 2024
-
REGULATORY CEA Expansion, Higher Copay Likely to Be Included in Minister Budget Deal
December 24, 2024
-
COMMENTARY Where Do Japan Drug Makers Stand? A Comparison with Other Industries and Mega Pharma Peers
December 24, 2024
-
REGULATORY Off-Year Price Revision to Hit 53% of Listed Drugs in 2025, Down from 69%
December 23, 2024
-
REGULATORY Three Ministers Agree on Off-Year Drug Price Revision in FY2025
December 20, 2024
-
REGULATORY Japan Set to Settle Off-Year Debate with “x1.0” Threshold for PMP Meds/Generics, “x0.5” for LLPs
December 20, 2024
-
REGULATORY Japan Weighs Tweaking “x0.625” Threshold to Narrow Off-Year Revision Coverage
December 19, 2024
-
REGULATORY Japan to Add Shingles Vaccines to NIP List from FY2025, Targeting Age 65
December 19, 2024
-
ORGANIZATION JPA Calls for Improving Package Units as Pharmacies Suffer with Unsold Stocks of Pricey Meds
December 19, 2024
-
BUSINESS Jazz’s Epilepsy Drug Candidate Nearing Submission as Japan Lifts Ban on Cannabis-Derived Meds
December 18, 2024
-
REGULATORY Ruling Bloc’s Draft Budget Policy Says Off-Year Revisions Could Alter, but DPP Calls for Explicit Mention of Repeal
December 17, 2024
-
BUSINESS Takeda Sees Up to US$20 Billion Sales Potential with 6 Late-Stage Assets
December 16, 2024
-
BUSINESS Amgen Japan Marks “Significant Milestone” with Tepezza Release, Eyes More Launches
December 16, 2024
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…